Key facts
- VentureMedGroup’s last known valuation is $60.2M (Oct 2025).
- It has raised $72.0M across 4 recorded rounds; the latest was Early Stage VC ($49.2M) in Oct 2025.
- Notable investors include S3 Ventures, Ohio Department of Development, Endeavour Vision, Global Cardiovascular Innovation Center, ProMedica Innovations — 7 tracked in total.
- VentureMedGroup has filed 4 Form Ds with the SEC since 2023, most recently Feb 2025 ($7.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for VentureMedGroup
Funding rounds
4 roundsAbout VentureMedGroup
Developer of endovascular medical devices intended to address unmet needs in treating peripheral arterial diseases. The company's devices safely and predictably modify plaque and stenosis by creating controlled, micro-incisions of any length in complex lesions of varying morphology and providing acute luminal gain, improved vessel compliance and consistent, good clinical revascularization outcomes in peripheral arterial disease (PAD), enabling healthcare providers to make vessel preparation simple, quick and cost-effective.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2012
- Employees
- 23
- Website
- flexvascular.com/
- Ownership
- Privately Held (backing)
VentureMedGroup doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VentureMedGroup shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VentureMedGroup in its N-PORT filings yet. We sweep new filings monthly.